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ORIGINAL ARTICLE
Pediatric reference intervals for general clinical chemistry components –
merging of studies from Denmark and Sweden
Peter Ridefelta, Linda Hilstedb, Anders Juulc, Dan Hellbergd and Pål Rustade
aDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden; bDepartment of Clinical Biochemistry,
Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark; cDepartment of Growth and Reproduction, Rigshospitalet
Copenhagen University Hospital, Copenhagen, Denmark; dCenter for Clinical Research, Falun, Sweden; eF€urst Medical Laboratory,
Oslo, Norway
ABSTRACT
Background: Reference intervals are crucial tools aiding clinicians when making medical decisions.
However, for children such values often are lacking or incomplete. The present study combines data
from separate pediatric reference interval studies of Denmark and Sweden in order to increase sample
size and to include also pre-school children who were lacking in the Danish study.
Methods: Results from two separate studies including 1988 healthy children and adolescents aged
6months to 18 years of age were merged and recalculated. Eighteen general clinical chemistry compo-
nents were measured on Abbott and Roche platforms. To facilitate commutability, the NFKK Reference
Serum X was used.
Results: Age- and gender-specific pediatric reference intervals were defined by calculating 2.5 and 97.5
percentiles.
Conclusion: The data generated are primarily applicable to a Nordic population, but could be used by
any laboratory if validated for the local patient population.
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Introduction
Reference intervals are important tools to aid the clinician in
differentiating between healthy and diseased populations. In
children, they should not only be derived from healthy
subjects [1], but also reflect the different phases of physio-
logical development from birth to adolescence [2]. However,
appropriate age- and gender-specific pediatric reference inter-
vals are often lacking, contain substantial age gaps, come
from obsolete methods, or derive from retrospective searches
of laboratory information system (LIS) with extraction of data
from healthy as well as diseased children [3–5]. Gaps may be
due to study recruitment being performed in school, and
missing preschool ages [5], or that collecting samples is par-
ticularly difficult from healthy infants [3].
Recent studies and projects have achieved major advance-
ments. The Canadian initiative CALIPER (Canadian
Laboratory Initiative on Paediatric Reference Intervals) has
published several papers on pediatric reference intervals
defined after measurements on blood sampled from healthy
children [6,7]. The German KiGGS study has successfully
determined reference intervals for numerous serum and
urine laboratory biomarkers using pediatric samples from
healthy participants [8]. Two Scandinavian groups from
Denmark [9] and Sweden [10–14] have also presented data
obtained after blood sampling of healthy children.
However, all these studies have limitations in the number
of participants included, which is especially evident for those
components where extensive partitioning is needed when
taking age and gender into consideration [15]. Often previ-
ous studies based of LIS searches had a limited number of
observations [4]. Recent studies have also tried to by-pass
the need for blood sampling from healthy children by doing
large-scale LIS searches or using new statistical approaches
[16,17]. Although the LIS search is relatively simple and
inexpensive, extra precautions must be taken not to include
large numbers of values from unhealthy individuals who
may be present in the database. These sampling techniques
assume that most results, even on hospital and clinic
patients, appear normal. No matter how they are calculated,
reference intervals generated from LIS searches should be
considered as estimates, as the underlying assumption that
most of the data come from healthy individuals may not be
correct. Thus, when possible, blood sampling from healthy
individuals is the preferred method [18].
Thus, the present study aims to merge the two data sets
from Denmark (COPENHAGEN Puberty Study) and Sweden
(Falun project) to define more reliable reference intervals for
the most common clinical chemistry components, measured
on modern analytic platforms and with transferability to
NFKK Reference Serum X [19]. The main reasons for
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combining these two separate studies was to increase sample
size, to include a broader span of ages (pre-school children
from Sweden) and to broaden the underlying population by
including subjects from two neighboring countries.
Materials and methods
Study subjects
Data on study design, inclusion and exclusion criteria and
ethics are presented elsewhere [10,20,21]. The Danish study
included a higher number of participants, but only included
school-age children. The Swedish study involved fewer
children but covered all ages from 6months to 18 years. The
subjects studied were not only associated to the medical health
care sector, but also consisted of healthy community-based
children and adolescents recruited in day care centers and
schools. The Swedish study included 653 healthy children and
adolescents and the Danish study included 1355 healthy chil-
dren and adolescents, from 0.5 to 18 years of age. Age distribu-
tion of the merged set is shown in Table 1. All children under
5 years of age were from Sweden. Subjects were non-fasting,
and exclusion of non-healthy was made depending on infor-
mation obtained from questionnaires, e.g., medical diagnoses
or drug treatments. The remaining participants were presumed
to be healthy. The collection of blood was performed during
2006 to 2008 for both the Danish and Swedish studies.
Laboratory analysis
Laboratory analysis included 18 commonly used clinical
chemistry components. The Danish samples were analyzed
on Roche Modular, and the Swedish samples were analyzed
on an Abbott Architect ci8200. Details for reagents and
calibrators were described previously [9] for the Danish data
set. For the Swedish study, the corresponding information is
also available; albumin, alanine transaminase (ALT), aspar-
tate transaminase (AST), creatine kinase (CK), bilirubin
[13]; alkaline phosphatase [14]; calcium, creatinine (enzym-
atic), potassium, magnesium, sodium, phosphate, urate [10];
cholesterol, lactate dehydrogenase (LD), triglycerides [11];
iron, transferrin [12]. Serum was used in the Swedish study,
and lithium-heparin plasma in the Danish investigation.
The commutable NFKK Reference Serum X (The Nordic
Society of Clinical Chemistry (NFKK)) has certified values
traceable to SI-units, or to an international measurement stand-
ard through reference measurement procedures and inter-
national reference materials, for the components: albumin,
calcium, cholesterol, creatinine, iron, potassium, magnesium,
sodium, triglycerides and urate. NFKK Reference Serum X also
has indicative values for the components: alkaline phosphatase,
ALT, AST, bilirubin, CK, LD, phosphate and transferrin, as
obtained in the frame of the Nordic Reference Interval Project
2000 [19]. The assigned values in the certificate of serum X
were valid until May 2011. The measurements within the pre-
sent projects were performed prior to the expiration date. All
reference values in the present project were recalculated accord-
ing to the formula Rc¼RT/Mr where Rc is the corrected
reference value and R is the measured reference value, T is
the certified or assigned value for NFKK Reference Serum X
and Mr is the mean of the 10 replicate measurements of
NFKK Reference Serum X in the series. Serum X was used at
the time of sample analysis for both studies. Occasional indi-
vidual data points are missing due to shortage of serum/
plasma for measurements of all components. These holes
comprise<0.5% of the full set of data.
Statistics
The raw data from the pediatric samples from the original
studies was reused. There was no re-analysis of blood sam-
ples. Furthermore, both studies did measure serum X along
with the pediatric samples. The statistical treatment of the
raw data was slightly different in the two original studies;
thus, all data were recalculated for the present compilation.
In the Danish study, raw data were adjusted according to
the measured value for serum X, with the formula men-
tioned above. In the Swedish study, only analytes with a
bias>5% compared to serum X were adjusted [10].
The data were visually inspected, and putative age- or gen-
der partitions were tested according to the principles of Lahti
et al. [22]. The criteria for no partitioning is that>0.9%
and<4.1% of each sub-distribution should be outside the 2.5-
and 97.5 percentiles of the common distribution.
Reasonable age limits and gender partitions were also
estimated by ‘qualified guessing’ from data in published
literature prior to exposure to the partitioning criteria. An
age group stated as 5–12 years of age, e.g., Table 2 includes
children from 5 to 12.99 years of age.
The statistical analysis was performed as previously
described for the Nordic Reference Interval Project 2000
[23]. Calculations were done using the computer program
RefVal 4.0 [24] based on the IFCC recommendations.
Automatic outlier detection as incorporated in RefVal 4.0,
using Dixon’s range test, was used. A simple non-parametric
method was used to calculate low- and high-suggested refer-
ence limits with 90% of confidence intervals according to
the 2.5- and 97.5 percentiles of the distribution of reference
values. Six subjects under 2 years of age with ALP>1000
Table 1. Age distribution of the healthy children and adolescents.
Years of age Total number of children Sweden Denmark
0.5–0.99 39 39 0
1 58 58 0
2 53 53 0
3 50 50 0
4 50 50 0
5 42 34 8
6 96 21 75
7 110 14 96
8 145 13 132
9 204 31 173
10 232 41 191
11 196 30 166
12 193 40 153
13 104 34 70
14 128 39 89
15 109 46 63
16 60 23 37
17 119 37 82
Years of age 1 include children 1– 1.99 years of age. The total number
of children was 1988 (653 from Sweden and 1335 from Denmark).
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Table 2. Calculated and suggested reference limits. NORIP reference limits are shown for comparison.
Component Unit Gender Age
Calculated reference limits with 90% of
confidence intervalsa
Number of
reference valuesd
Suggested
reference
limits
Low High Low High
Alanine trans-aminase U/L FM 0.5–5 8 8–8 19 18–25 1986 292 8 19
6–17 31 30–33 1694 31
F 18 – 10 45
M – 70
Albumin g/L FM 0.5–6 38 37–39 46 46–47 1988 389 38 46
7–12 47 47–48 1079 47
13–17 49 49–50 520 49
18 – 36 48
Alkaline phos-Phatase U/L FM 0.5–1 124 120–133 470 358–544b 1567 91-1 120 470
2–5 287 255–325 194-1 290
6–9 366 355–392 555 370
10–11 436 398–465 426 440
F 12–13 389 346–544 152 390
M 525 469–616 144 530
F 14–15 47 42–55 271 240–314 414 137 50 270
M 418 374–479b 100 420
F 16–17 124 104–149b 99 120
M 275 212–373b 78 280
FM 18 – 35 105
Aspartate trans-aminase U/L FM 0.5–1 25 25–26 64 55–74b 634 94-1 25 64
2–8 47 45–48 1884 47
9–17 17 16–17 1344 17
F 18 – 15 35
M – 45
Bilirubin mmol/L FM 0.5–5 2 2–2 8 7–9 1981-1 292 2 8
6–10 18 15–20 782 18
11–17 24 21–28 907-1 24
18 5 – 25 – 5 25
Calcium mmol/L FM 0.5–0.99 2.40 –c 2.79 –c 39 2.40 2.80
1–4 2.29 2.27–2.32 2.64 2.62–2.65 211 2.30 2.64
5–12 2.24 2.21–2.26 2.59 2.58–2.60 1211 1729 2.24 2.60
13–17 2.09 2.05–2.15 518 2.10
18 – 2.15 2.51
Cholesterol mmol/L FM 0.5–17 2.7 2.7–2.7 5.5 5.5–5.7 1986 2.7 5.5
18 2.9 – 6.1 – 2.9 6.1
Creatine kinase U/L FM 0.5–1 35 30–40 386 262–509b 250 97 35 390
F 2–4 241 224–254 528-1 240
M 301 259–344 450 300
F 5–10 52 49–56 241 224–254 1732 528-1 50 240
M 301 259–344 450 300
F 11–17 328 275–442 508 330
M 659 534–973 399 660
F 18 – 35 210
M – 50 400
Creatinine mmol/L FM 0.5–2 19 14–20 46 42–59 150 19 46
3–5 24 22–25 49 42–53 142-1 24 49
6–8 28 25–29 51 49–53 349 28 51
9–12 33 33–34 63 61–65 821 33 63
F 13–17 39 36–41 77 75–82 293 39 77
M 44 39–47 92 87–98 227 44 92
F 18 – 45 90
M – 60 105
Iron mmol/L FM 0.5–0.99 4.1 3.5–5.1 17.0 –c 248 38 4.0 17
1–4 28.1 25.2–35.0 210 28
5–12 6.8 6.2–7.6 29.9 29.4–31.3 1732 1212 7.0 30
13–17 34.9 33.0–37.5 520 35
18 – 9.0 34
Lactate dehydro-genase U/L FM 0.5–12 133 129–136 317 313–326 1977 1457-1 130 320
13–17 273 261–280 520 270
18 – 105 205
Magnesium mmol/L FM 0.5–3 0.77 0.76–0.79 0.96 0.95–0.96 200 1982 0.77 0.96
4–17 0.72 0.71–0.73 1782 0.72
18 – 0.71 0.94
Phosphate mmol/L FM 0.5–2 1.50 1.40–1.55 2.08 2.01–2.18 150 200 1.50 2.08
3 1.34 1.28–1.39 100 1.34
4 1.80 1.78-1.84 1264 1.80
5–12 1.10 1.08-1.13 1214 1.10
13–17 0.86 0.80-0.90 1.72 1.69-1.77 518 0.86 1.72
F 18 – 0.85 1.50
M – 0.75 1.65
(continued)
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Table 2. Continued
Component Unit Gender Age
Calculated reference limits with 90% of
confidence intervalsa
Number of
reference valuesd
Suggested
reference
limits
Low High Low High
Potassium mmol/L FM 0.5–4 3.8 3.7–3.9 5.5 5.1–5.8 250 3.8 5.5
5–17 3.3 3.3-3.3 4.6 4.5–4.6 1736 3.3 4.6
18 – 3.5 4.4
Sodium mmol/L FM 0.5–17 136 136–136 146 146–146 1952 136 146
18 – 137 144
Transferrin g/L FM 0.5–4 2.21 2.05–2.28 3.47 3.38–3.61 200 2.20 3.50
F 5–12 2.13 2.11–2.17 3.36 3.33–3.45 1738 667 2.10 3.40
M 3.31 3.28–3.38 551 3.30
F 13–17 3.96 3.83–4.34 293 4.00
M 3.59 3.42–3.87 227 3.60
FM 18 – 1.87 3.19
Triglycerides mmol/L FM 0.5–17 0.36 0.34–0.36 2.19 2.11–2.37 1987 0.36 2.19
18 – 0.45 2.6
Urate mmol/L F 0.5–9 140 133–146 320 317–331 1087a 1078 140 320
M 136 125–145 672 140
F 10–12 140 133–146 342 336–352 1087a 646a 140 340
M 136 125–145 364 345–383 672 267 140 360
F 13–17 140 133–146 342 336–352 1087a 646a 140 340
M 186 157–205 462 430–480 227-1 227-1 190 460
F 18 – 155 350
M – 230 480
Grey-shaded rows represent NORIP reference intervals for adults. An age group specified as 0.5–5 includes children from 0.50 to 5.99 years of age.
aThe number is the sum for several age groups sharing the same reference interval.
bThe confidence interval has been calculated with the bootstrap method because of too few results.
cToo few reference values to calculate confidence interval.
d“1” means that one outlier has been removed before calculating the reference interval.
Figure 1. Creatinine concentrations (mmol/L) in individual children, separated by gender.
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U/L who presumably had the diagnosis transient hyperphos-
phatasemia were eliminated before outlier calculations [14].
Results
The present study proposes reference intervals for 18 clinical
chemistry components derived from measurements on 1335
Danish and 653 Swedish healthy children and adolescents.
Low- and high-suggested reference limits, 90% of confidence
intervals and outliers detected are shown in Table 2.
For comparisons, Table 2 also includes the proposed refer-
ence intervals for the youngest group of adults, as suggested
by the NORIP project [23].
In general, the reference intervals generated from the merged
data set only caused minor changes of the limits, except for
creatinine. Due to the continuous age-related changes creatinine
is one of the most challenging components when defining age-
and sex-specific pediatric reference intervals [6]. In Figure 1, the
steady rise of creatinine is shown, as well as the gender differen-
ces that are evident from 12years of age. Figure 2 shows the
presently suggested reference intervals for males, as well as refer-
ence intervals suggested for enzymatic creatinine in some recent
papers [6,10,25]. Lower limits agree well, but the upper limits
show some differences. However, different age and gender parti-
tioning in different studies makes direct comparisons difficult
with a component as creatinine with a marked and continuous
increase with age.
Alkaline phosphatase displays complex age and gender
changes [26]. These changes are illustrated in Figure 3 showing
the individual results of the alkaline phosphatase measurements.
The suggested reference intervals for females from the present
study compared to those from the CALIPER project are
depicted in Figure 4. Alkaline phosphatase concentrations in
blood are closely linked to growth which requires extensive par-
titioning for age, particularly around puberty.
Discussion
This study reports age- and gender-specific reference intervals
for children and adolescents 6months to 18 years of age, after
blood sampling from 1988 participants from Denmark and
Sweden. Reference intervals for 18 clinical chemistry compo-
nents were calculated with non-parametric methods after
merging of two previously published data sets. By including
measurements of NFKK Reference Serum X, commutability
of the reference intervals was obtained.
Although reference values for most analytes were similar
between the two countries some differences were observed.
Two exceptions might be related to the blood sampling tubes
used. Potassium was approximately 0.4mmol/L lower in the
Figure 2. Suggested reference intervals for creatinine for male children from the Colantonio et al.’s study [6], Ceriotto et al.’s study [25] and the two original data
sets [9,10], as well as the presently suggested intervals (DEN/SWE). For comparison NORIP [23] intervals for males 18–19 years of age are included.
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Danish subjects. This might be due to the use of serum in
Sweden and lithium heparin plasma in Denmark. In the ori-
ginal NORIP study on adults there was a 0.14 to 0.26mmol/L
difference in the suggested reference interval limits for serum
and plasma [23]. The suggested reference intervals in Table 1
shows figures for the youngest children (6months to 4 years)
based on the Swedish data from serum samples, and the com-
bined figures from serum and plasma measurements for the
older children. Previous studies have also shown slightly
higher potassium values for children under 1 year of age and
children below 16 years of age compared to adults [4].
Nevertheless, it is reasonable that the main part of the
observed difference is due to different sampling tubes.
Similarly, serum and plasma may yield differences for phos-
phate. In the NORIP study on adults, plasma measurements
were about 7% lower than serum determination [23].
Correspondingly, in the present study measurements on
plasma gave 6–7% higher results (data not shown).
Interpretation of alkaline phosphatase activity in children
is challenging due to extensive changes with growth and
puberty leading to distinct sex- and age-specific dynamics
[26]. The present study gave similar results as the CALIPER
project and the Loh and Metz’s study [2,6], with a slowly
increasing level up to 10 years of age, and then peaks dur-
ing puberty with females peaking at slightly lower age
(Figure 3). These peaks call for extensive partitioning for
age and highlight the problem of representing the age and
gender dependence of alkaline phosphatase concentrations
with distinct age groups. Continuous reference intervals
would likely capture the changes during puberty more
accurately than discrete age groups. Thus, some of the dif-
ferences between the present study and the CALIPER, par-
ticularly between 13 and 16 years of age, might be due to
the specific age groups chosen for partitioning of the ALP
peak during puberty. All laboratories do not report alkaline
phosphatase results with lower limits for the reference
interval. The presently suggested intervals include lower
limits to draw attention to the abnormally low levels of
ALP associated with hypophosphatasia, a rare inborn error
of metabolism causing bone disease [27].
One drawback with the present study is that age groups
from birth to 6months of age is lacking. This is a particularly
challenging age group due to the ethical aspects of blood sam-
pling, and also to the low blood volume available in these chil-
dren. The large CALIPER study had similar problems, and
although most samples came from healthy children, those
under the age of 1 year was leftover samples from selected
outpatient clinics, including dentistry, fracture, and plastics
[6]. Thus, this age group still presents a challenge. Such crit-
ical gaps compromise the conditions for paediatricians to
accurately diagnose medical conditions in their patients [3].
In addition, the calculations might be influenced by the
fact that for children in school age, there were a higher num-
ber of children from Denmark, and for pre-school children all
participants came from Sweden. Thus, for children 6–17 years
of age the suggested reference intervals reflects the Danish
population more than the Swedish, and putative differences
between populations might affect the calculated reference
Figure 3. Alkaline phosphatase concentrations (U/L) in individual children, separated by gender.
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intervals. In addition, the unbalanced raw data could influence
the age and gender groups chosen for partitioning.
The major strength with the present study is that the
number of children included is substantially increased,
including the pre-school children. CLSI recommendations
call for at least 120 observations for each group after parti-
tioning when calculating reference intervals [18]. In the pre-
sent data set, this recommendation is met in 90% of cases
(79 out 88). Due to ethical reasons, ethnic groups were not
recorded in the original studies, although the participants
mainly were of Danish or Swedish origin. Thus, these
suggested intervals are based on a Nordic population, but
could be used by any laboratory if validated for the local
patient population.
Furthermore, the set-up of this investigation ensures that
the reference intervals reported in the present study can be
used, irrespective of instrumentation, for the components
with certified values in the NFKK Reference Serum X.
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